ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03533114
Recruitment Status : Not yet recruiting
First Posted : May 22, 2018
Last Update Posted : June 7, 2018
Sponsor:
Information provided by (Responsible Party):
Jazz Pharmaceuticals

Brief Summary:
This is a study of the efficacy and safety of JZP-258, an oxybate mixed-salts oral solution being developed as a low sodium alternative product for Xyrem.

Condition or disease Intervention/treatment Phase
Idiopathic Hypersomnia Drug: JZP-258 Drug: Placebo Oral Tablet Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension
Estimated Study Start Date : September 2018
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: JZP-258
JZP-258 at the stable dose and regimen for 2 weeks.
Drug: JZP-258
Subjects randomized to JZP-258 will receive the dose taken at the end of the Stable Dose Period.

Placebo Comparator: Placebo
Placebo will be administered at a volume and regimen equivalent to the JZP-258 dose and regimen for 2 weeks.
Drug: Placebo Oral Tablet
Subjects randomized to Placebo will receive an oral solution at a volume and regimen equivalent to the JZP-258 dose taken at the end of the Stable Dose Period.




Primary Outcome Measures :
  1. Change in Epworth Sleepiness Scale (ESS) score [ Time Frame: 2 Weeks ]

    Change in ESS score from the end of the Stable Dose Period to the end of the Double-blind Randomized Withdrawal Period.

    The ESS provides a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. The ESS consists of 8 questions, each scored on a scale from 0-3, with a total score range between 0 and 24; lower ESS scores are better, indicating less daytime sleepiness; higher ESS scores are worse, indicating more severe sleepiness.



Secondary Outcome Measures :
  1. Percentage of Subjects Reported as Worse on the Patient Global Impression of Change (PGIc) [ Time Frame: 2 Weeks ]
    Percentage of subjects reported as worse (minimally, much, or very much) on the PGIc at the end of the Double-blind Randomized Withdrawal Period

  2. Change in Maintenance of Wakefulness Test (MWT) [ Time Frame: 2 Weeks ]
    Change in MWT (in minutes) as determined from the first 4 trials of a 40-minute MWT from the end of the Stable Dose Period to the end of the Double-blind Randomized Withdrawal Period

  3. Percentage of Subjects Reported as Worse on the Clinical Global Impression of Change (CGIc) [ Time Frame: 2 Weeks ]
    Percentage of subjects reported as worse (minimally, much, or very much) on the CGIc at the end of the Double-blind Randomized Withdrawal Period

  4. Change in Total Score on the FOSQ-10 [ Time Frame: 2 Weeks ]

    Change in total score on the FOSQ-10 from the end of the Stable Dose Period to the end of the Double-blind Randomized Withdrawal Period.

    The FOSQ-10 provides a measure of the impact of sleepiness on activities of daily living. The FOSQ-10 consists of 10 questions, each scored on a scale from 1-4. The total score is derived by the mean of the 5 subscale scores, multiplied by 5, resulting in a possible range of scores between 5 to 20; lower FOSQ-10 scores are worse, indicating more difficulty carrying out activities; higher FOSQ-10 scores are better, indicating less difficulty carrying out activities.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female between 18 and 70 years of age, inclusive, at the time of consent.
  2. Have a primary diagnosis of IH according to the International Classification of Sleep Disorders ICSD-2 or ICSD-3 criteria.
  3. At the Screening Visit and the Baseline Visit, subjects who are not on Xyrem at study entry must have ESS scores ≥ 11 (as assessed with a look-back period of 1 week).
  4. If currently treated with Xyrem, must have documented clinical improvement of EDS per Investigator's clinical judgment.
  5. Average nightly total sleep time of ≥ 7 hours, per subject history. Total sleep time will be confirmed by Investigator's review of sleep diaries collected during the final 2 weeks of the Screening Period.
  6. If currently treated with stimulants and / or alerting agents or nicotine replacement therapy, must have been taking the same regimen and dose for at least 2 months prior to screening and must agree to take the same dose leading up to and throughout the Double-blind Randomized Withdrawal Period.
  7. Have used a medically acceptable method of contraception for at least 2 months prior to the first dose of study drug and consent to use a medically acceptable method of contraception from the first dose of study drug, throughout the entire study period, and for 90 days after the last dose of study drug.

Exclusion Criteria:

  1. Hypersomnia due to another medical, behavioral, or psychiatric disorder condition.
  2. Evidence of untreated or inadequately treated sleep-disordered breathing.
  3. Clinically significant parasomnias (eg, sleep walking, rapid eye movement sleep behavior disorder, etc.).
  4. Current or past (within 1 year) major depressive episode according to DSM-5 criteria. Patients with depression under control are allowed per the judgment of the Investigator or the treating physician and the anti-depressant treatment has to be stable for at least 6 months prior to Screening and remain stable for the duration of the study.
  5. Current suicidal risk as determined from history by presence of active suicidal ideation as indicated by positive response to item #4 or #5 on C-SSRS, or any history of suicide attempt.
  6. Occupation requiring nighttime shift work or variable shift work with early work start times or other occupations that could affect the safety of the subject per the judgment of the Investigator.
  7. Treatment or planned treatment with benzodiazepines, non-benzodiazepine anxiolytics / hypnotics / sedatives, neuroleptics, opioids, barbiturates, and medications containing valproic acid or its sodium salt (eg, depakene and depakote) within 2 weeks prior to enrollment. Discontinuation for the purpose of this study is permitted only if considered medically appropriate by the Investigator, and subjects must abstain from these medications during the study.
  8. Current or past substance use disorder (including alcohol) according to DSM-5 criteria, or the subject is unwilling to refrain from consuming alcohol, cannabinoids, or prohibited medications during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03533114


Contacts
Contact: Associate Director Clinical Trial Disclosure 2158323750 ClinicalTrialDisclosure@JazzPharma.com

Sponsors and Collaborators
Jazz Pharmaceuticals

Responsible Party: Jazz Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03533114     History of Changes
Other Study ID Numbers: JZP080-301
First Posted: May 22, 2018    Key Record Dates
Last Update Posted: June 7, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Disorders of Excessive Somnolence
Hypersomnolence, Idiopathic
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders